Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Encycle Therapeutics

Encycle Therapeutics
2012 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Corporate LATEST DEAL TYPE (Announced)
$500K LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of drugs designed to exploit a novel synthetic method to generate drug-like cyclic peptides. The company's drugs are generated by several scaffolds that are membrane permeable and orally bioavailable products, such as nacellins which are ideal for targeting protein-protein interactions, enabling patients to get cured from inflammatory bowel disease and other inflammatory disorders.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 101 College Street
  • Suite 314
  • Toronto, Ontario M5G 1L7
  • Canada

+1 (647) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Encycle Therapeutics’s full profile, request a free trial.

Encycle Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Corporate 01-Nov-2017 $500K 00.000 Announced Startup
4. Early Stage VC 30-Sep-2015 00.000 00.000 Completed Startup
3. Early Stage VC 16-Jun-2015 00000 00.000 Completed Startup
2. Grant 17-Nov-2014 $2.5M Completed Startup
1. Early Stage VC 11-Nov-2014 $2.5M $2.5M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Encycle Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Accel-Rx Accelerator/Incubator Minority 000 0000 000000 0
MaRS Investment Accelerator Fund Venture Capital Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
CQDM Government Minority 000 0000 000000 0
MaRS Innovation Not-For-Profit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Encycle Therapeutics Executive Team (3)

Name Title Board
Seat
Contact
Info
Jeffrey Coull Ph.D President, Chief Executive Officer & Board Member
Andrei Yudin Ph.D Board Member & Scientific Founder, SAB
Andrew Roughton Ph.D Vice President, Discovery and Operations & Board Observer

Encycle Therapeutics Board Members (12)

Name Representing Role Since Contact
Info
Andrei Yudin Ph.D Encycle Therapeutics Board Member & Scientific Founder, SAB 000 0000
Andrew Roughton Ph.D Encycle Therapeutics Vice President, Discovery and Operations & Board Observer 000 0000
Frederic Lemaitre Auger Ph.D Self Board Member 000 0000
Jeffrey Coull Ph.D Encycle Therapeutics President, Chief Executive Officer & Board Member 000 0000
Jennifer Fraser Encycle Therapeutics Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 12 board members. Get the full list »